Procore signs multi-year strategic collaboration agreement with AWS
On Friday, Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently trading at $43.52, with a market capitalization of $4.02 billion, InvestingPro data indicates the stock is currently undervalued. The firm's analysts highlighted the progress of Ultragenyx's DTX301 program, a gene therapy for Ornithine Transcarbamylase (OTC) deficiency. They noted the completion of Phase 3 enrollment and a recent protocol amendment as significant developments. The company has demonstrated strong revenue growth of 27.44% over the last twelve months, according to InvestingPro data.
The analysts also pointed to setrusumab's upcoming clinical readouts for osteogenesis imperfecta (OI), expected in mid-2025, as a potential catalyst for the stock. They suggested that positive results could lead to a doubling of the share price. Additionally, the analysts believe that Ultragenyx's earlier stage gene therapy pipeline holds potential upside not currently reflected in the stock's valuation.
Cantor Fitzgerald's outlook includes a 30% probability of success for the OTC deficiency program and projects unadjusted peak sales of approximately $560 million. They describe Ultragenyx's situation as a classic high-risk, high-reward scenario, with significant developments expected in the near to mid-term future for the company's clinical programs. With a healthy current ratio of 2.81 and three analysts recently revising earnings upward, the company shows promising financial indicators. For deeper insights into Ultragenyx's financial health and growth potential, investors can access comprehensive analysis through InvestingPro's detailed research reports.
In other recent news, Ultragenyx Pharmaceutical Inc. has been the subject of various analyst ratings and has reported significant developments in its pipeline. Goldman Sachs maintained a Buy rating on Ultragenyx with a steady price target of $78.00, underscoring the company's fourth-quarter total revenue of $164.9 million that surpassed estimates. Ultragenyx's full-year 2025 revenue guidance is projected to be between $640 million and $670 million, indicating an optimistic outlook.
On the other hand, Truist Securities reiterated a Buy rating with a price target of $140, highlighting Ultragenyx's path to GAAP profitability by 2027. The firm also emphasized the progress of the Phase 3 OBRIT study, which could lead to significant advancements in the company's pipeline of treatments.
RBC Capital Markets reiterated its Outperform rating, expressing optimism about Ultragenyx's drug for Osteogenesis Imperfecta. The firm drew parallels between the drug's mechanism of action and treatments for osteoporosis, suggesting potential success for the drug.
In terms of product development, Ultragenyx unveiled promising data on its experimental gene therapy, UX111, for Sanfilippo syndrome type A. The therapy led to significant cognitive improvements in patients, an encouraging development that was part of a Biologics License Application submitted to the FDA. The decision is anticipated in the second half of 2025. These are the latest developments in Ultragenyx's endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.